FDA Approves MIXED SALTS OF A SINGLE ENTITY AMPHETAMINE PRODUCT XR — SpecGx LLC
SpecGx LLC today received FDA approval for its generic version of the ADHD drug Mixed Salts of a Single Entity Amphetamine Product XR, an event that signals increased competition in the psychostimulant market and is expected to impact the pricing dynamics of the branded medication.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day